Phase II Trial Of Yttrium-90-Ibritumomab Tiuxetan (Zevalin®) Radioimmunotherapy After Cytoreduction With ESHAP Chemotherapy In Patients With Relapsed Follicular Non-Hodgkin's Lymphoma
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 18 Apr 2018
At a glance
- Drugs Ibritumomab tiuxetan (Primary) ; Cisplatin; Cytarabine; Etoposide; Methylprednisolone; Rituximab
- Indications Follicular lymphoma
- Focus Therapeutic Use
- 12 Apr 2018 Planned End Date changed from 31 Dec 2018 to 31 Dec 2019.
- 12 Apr 2018 Planned primary completion date changed from 31 Dec 2017 to 31 Dec 2018.
- 07 Mar 2017 Planned End Date changed from 1 Dec 2016 to 31 Dec 2018.